According to a report by MarketBeat.com on January 25th, UBS Group research analysts have downgraded their rating on Philip Morris International from "buy" to "sell" in a research report released to investors on Tuesday. They currently have a target price of $86.50 for the stock, which is lower than the previous target price of $105.00. UBS Group's target price represents a potential decrease of 4.81% from the company's previous closing price.
According to the data, institutional investors have increased their stake in Philip Morris International, indicating that they still have confidence in the company.
Philip Morris International (PMI) is primarily engaged in the production and sale of tobacco and non-tobacco products. These products include heated tobacco, e-cigarettes, and oral nicotine products marketed under various brands such as IQOS and ZYN.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
